search
Back to results

Study of Leptin for the Treatment of Hypothalamic Amenorrhea

Primary Purpose

Amenorrhea

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
r-metHuLeptin
Oral Contraceptive Pills (OCPs)
Placebo
Sponsored by
Beth Israel Deaconess Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Amenorrhea focused on measuring leptin, hypothalamic amenorrhea, exercise-induced amenorrhea, neuroendocrine function, bone metabolism

Eligibility Criteria

18 Years - 35 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion criteria for HA subjects Hypothalamic amenorrhea of at least 6 months duration with low or normal LH and FSH, e.g. due to strenuous exercise (running >20 miles per week or equivalent) or low weight Can be secondary HA OR primary HA with some pubertal development and normal screening labs Age 18-35 years old Body weight within +/- 15% of ideal body weight and stable for 6 months (no change > 5 lbs) Baseline leptin <5 ng/mL (except for the Cognitive Sub-Study Baseline visit where baseline leptin will be greater than 5ng/mL) Inclusion criteria for eumenorrheic controls for Reward Sub-study Normal menstrual cycles (between 25 and 35 days) Age 18-35 Body weight within +/- 15% of ideal body weight and stable 6 months (no change > 5 lbs) Baseline leptin >5 ng/mL Exclusion criteria: We will exclude subjects with: Significant medical history that may affect the concentrations of the hormones to studied or ability to participate in the study renal or hepatic disease (creatinine > 1.4, AST/ALT > 2x upper limit of normal) diagnosed diabetes mellitus myocardial ischemia malignancy (other than basal cell carcinoma of the skin or in situ carcinoma of the cervix) malabsorption alcoholism, drug abuse, or smoking active eating disorder depression or other psychiatric disease anemia (Hb10 gm/dL on 2 occasions) Conditions that are contraindicated for oral contraceptive use: Thrombophlebitis or thromboembolic disorders A past history of deep vein thrombophlebitis or thromboembolic disorders Cerebral vascular or coronary artery disease Known or suspected carcinoma of the breast Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia Undiagnosed abnormal genital bleeding Hepatic adenomas or carcinomas Cholestatic jaundice of pregnancy or jaundice with prior OCP use Other endocrine causes of amenorrhea, e.g. hyperprolactinemia hypothyroidism or hyperthyroidism Cushing's syndrome congenital adrenal hyperplasia (elevated 17 OH progesterone) polycystic ovarian syndrome (elevated androgens or LH/FSH ratio >1.5) primary ovarian failure (elevated FSH) On medications known to affect the hormones to be measured such as glucocorticoids anti seizure medications thyroid hormones estrogen (must be off at least 3 months prior to participating in the study) A known history of anaphylaxis or anaphylactoid-like reactions, or a known hypersensitivity to E. Coli derived proteins Breast feeding, pregnant, or wanting to become pregnant during the next 6 months. We will screen for these conditions through a detailed history and systems review, physical examination, laboratory evaluation (as described above in Screening Methods), and EKG. In the Reward Sub-study subjects will be asked to fill out a standard BIDMC MRI safety screening form prior to entering the magnet.

Sites / Locations

  • Beth Israel Deaconess Medical Center General Clinical Research Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

r-metHuLeptin

Oral Contraceptive Pills (OCPs)

Arm Description

r-metHuLeptin administered subcutaneously.

PLACEBO

Outcomes

Primary Outcome Measures

the Difference Between the Placebo and Leptin Treated Groups in the Change in Bone Mineral Content(BMC) at the Anteroposterior (AP) Spine From Baseline to 36 Weeks

Secondary Outcome Measures

Bone Markers - Ctx and Sclerostin
Body Composition BMI
Total Body BMD
Body Fat
Total Body BMD
Lumbar BMD
Radial BMD
Hip BMD

Full Information

First Posted
August 11, 2005
Last Updated
April 13, 2017
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Research Resources (NCRR), Amgen
search

1. Study Identification

Unique Protocol Identification Number
NCT00130117
Brief Title
Study of Leptin for the Treatment of Hypothalamic Amenorrhea
Official Title
Randomized, Double-blind, Placebo-controlled Trial of Human Recombinant Leptin (r-metHuLeptin) for the Treatment of Hypothalamic (Exercise-Induced) Amenorrhea
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
April 2010 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
December 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Research Resources (NCRR), Amgen

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether administration of an investigational medication called leptin (r-metHuLeptin) in replacement doses can improve bone health, reproductive function, hormone levels, immune function, and overall sense of well-being in women with hypothalamic (exercise-induced) amenorrhea (HA) who are being treated with oral contraceptive pills (OCPs), compared to placebo. Women with hypothalamic amenorrhea have low leptin levels. This study is based on the hypothesis that the relative leptin deficiency in women with hypothalamic (exercise-induced) amenorrhea may be the reason for the lack of menstrual cycles, hormone abnormalities, and bone loss associated with this condition.
Detailed Description
Leptin is a hormone secreted by fat cells under normal conditions and acts in the brain to regulate energy usage and hormone levels. Women with HA who do not have regular periods have low leptin levels and may also have other hormone abnormalities as well as loss of bone density (osteopenia or osteoporosis). This study will evaluate how leptin (a fat cell hormone that normally circulates in the blood) affects bone density, menstrual periods, hormone levels, bone metabolism (how bone forms and turns over), immune function (how well the body can fight infection), metabolic rate (how many calories are used at rest), and overall sense of well-being and appetite in women with HA (i.e. no regular menstrual periods due to low levels of pituitary hormones that regulate estrogen production from the ovary). It will also investigate whether leptin replacement can be used as an adjunct to the current standard of care for HA patients, i.e. OCPs. Part A is a Randomized, placebo-controlled 36-week study. Part B is an Optional open-label 52-week study. There will also be an optional Reward Sub-study, including healthy controls, designed to investigate leptin's relation to reward processing by collecting participants' brain and behavioral responses to images (e.g., pictures of food vs. non-food). Brain responses will be collected and will also be assessed via functional Magnetic Resonance Imaging (fMRI). Comparison: Part A = leptin-treated group to placebo-treated group and Part B optional sub study = leptin-treated group to health controls

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amenorrhea
Keywords
leptin, hypothalamic amenorrhea, exercise-induced amenorrhea, neuroendocrine function, bone metabolism

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
r-metHuLeptin
Arm Type
Experimental
Arm Description
r-metHuLeptin administered subcutaneously.
Arm Title
Oral Contraceptive Pills (OCPs)
Arm Type
Placebo Comparator
Arm Description
PLACEBO
Intervention Type
Drug
Intervention Name(s)
r-metHuLeptin
Other Intervention Name(s)
metreleptin
Intervention Description
Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Intervention Type
Drug
Intervention Name(s)
Oral Contraceptive Pills (OCPs)
Other Intervention Name(s)
OCPs
Intervention Description
Sprintec taken orally once daily.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
placebo (no active medication)
Primary Outcome Measure Information:
Title
the Difference Between the Placebo and Leptin Treated Groups in the Change in Bone Mineral Content(BMC) at the Anteroposterior (AP) Spine From Baseline to 36 Weeks
Time Frame
36 weeks
Secondary Outcome Measure Information:
Title
Bone Markers - Ctx and Sclerostin
Time Frame
36 weeks
Title
Body Composition BMI
Time Frame
36 weeks
Title
Total Body BMD
Time Frame
36 weeks
Title
Body Fat
Time Frame
36 weeks
Title
Total Body BMD
Time Frame
9 months
Title
Lumbar BMD
Time Frame
9 months
Title
Radial BMD
Time Frame
9 months
Title
Hip BMD
Time Frame
9months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria for HA subjects Hypothalamic amenorrhea of at least 6 months duration with low or normal LH and FSH, e.g. due to strenuous exercise (running >20 miles per week or equivalent) or low weight Can be secondary HA OR primary HA with some pubertal development and normal screening labs Age 18-35 years old Body weight within +/- 15% of ideal body weight and stable for 6 months (no change > 5 lbs) Baseline leptin <5 ng/mL (except for the Cognitive Sub-Study Baseline visit where baseline leptin will be greater than 5ng/mL) Inclusion criteria for eumenorrheic controls for Reward Sub-study Normal menstrual cycles (between 25 and 35 days) Age 18-35 Body weight within +/- 15% of ideal body weight and stable 6 months (no change > 5 lbs) Baseline leptin >5 ng/mL Exclusion criteria: We will exclude subjects with: Significant medical history that may affect the concentrations of the hormones to studied or ability to participate in the study renal or hepatic disease (creatinine > 1.4, AST/ALT > 2x upper limit of normal) diagnosed diabetes mellitus myocardial ischemia malignancy (other than basal cell carcinoma of the skin or in situ carcinoma of the cervix) malabsorption alcoholism, drug abuse, or smoking active eating disorder depression or other psychiatric disease anemia (Hb10 gm/dL on 2 occasions) Conditions that are contraindicated for oral contraceptive use: Thrombophlebitis or thromboembolic disorders A past history of deep vein thrombophlebitis or thromboembolic disorders Cerebral vascular or coronary artery disease Known or suspected carcinoma of the breast Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia Undiagnosed abnormal genital bleeding Hepatic adenomas or carcinomas Cholestatic jaundice of pregnancy or jaundice with prior OCP use Other endocrine causes of amenorrhea, e.g. hyperprolactinemia hypothyroidism or hyperthyroidism Cushing's syndrome congenital adrenal hyperplasia (elevated 17 OH progesterone) polycystic ovarian syndrome (elevated androgens or LH/FSH ratio >1.5) primary ovarian failure (elevated FSH) On medications known to affect the hormones to be measured such as glucocorticoids anti seizure medications thyroid hormones estrogen (must be off at least 3 months prior to participating in the study) A known history of anaphylaxis or anaphylactoid-like reactions, or a known hypersensitivity to E. Coli derived proteins Breast feeding, pregnant, or wanting to become pregnant during the next 6 months. We will screen for these conditions through a detailed history and systems review, physical examination, laboratory evaluation (as described above in Screening Methods), and EKG. In the Reward Sub-study subjects will be asked to fill out a standard BIDMC MRI safety screening form prior to entering the magnet.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christos S Mantzoros, MD, ScD
Organizational Affiliation
Beth Israel Deaconess Medical Center, Harvard Medical School
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center General Clinical Research Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
15342807
Citation
Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004 Sep 2;351(10):987-97. doi: 10.1056/NEJMoa040388.
Results Reference
background
PubMed Identifier
21791620
Citation
Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, Hamnvik OP, Koniaris A. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011 Oct;301(4):E567-84. doi: 10.1152/ajpendo.00315.2011. Epub 2011 Jul 26.
Results Reference
background
PubMed Identifier
21741057
Citation
Sienkiewicz E, Magkos F, Aronis KN, Brinkoetter M, Chamberland JP, Chou S, Arampatzi KM, Gao C, Koniaris A, Mantzoros CS. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. Metabolism. 2011 Sep;60(9):1211-21. doi: 10.1016/j.metabol.2011.05.016. Epub 2011 Jul 7.
Results Reference
result
PubMed Identifier
21464293
Citation
Chou SH, Chamberland JP, Liu X, Matarese G, Gao C, Stefanakis R, Brinkoetter MT, Gong H, Arampatzi K, Mantzoros CS. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6585-90. doi: 10.1073/pnas.1015674108. Epub 2011 Apr 4.
Results Reference
result
PubMed Identifier
33051459
Citation
Chrysafi P, Perakakis N, Farr OM, Stefanakis K, Peradze N, Sala-Vila A, Mantzoros CS. Leptin alters energy intake and fat mass but not energy expenditure in lean subjects. Nat Commun. 2020 Oct 13;11(1):5145. doi: 10.1038/s41467-020-18885-9.
Results Reference
derived
PubMed Identifier
33045195
Citation
Bouzoni E, Perakakis N, Mantzoros CS. Circulating profile of Activin-Follistatin-Inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment. Metabolism. 2020 Dec;113:154392. doi: 10.1016/j.metabol.2020.154392. Epub 2020 Oct 10.
Results Reference
derived
PubMed Identifier
25148234
Citation
Foo JP, Polyzos SA, Anastasilakis AD, Chou S, Mantzoros CS. The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea. J Clin Endocrinol Metab. 2014 Nov;99(11):E2252-8. doi: 10.1210/jc.2014-2491. Epub 2014 Aug 22.
Results Reference
derived
PubMed Identifier
24703486
Citation
Hwang JJ, Thakkar B, Chamberland JP, Mantzoros CS. Circulating fetuin-A levels are not affected by short and long-term energy deprivation and/or by leptin administration. Metabolism. 2014 Jun;63(6):754-9. doi: 10.1016/j.metabol.2014.02.006. Epub 2014 Feb 17.
Results Reference
derived
PubMed Identifier
23382191
Citation
Matarese G, La Rocca C, Moon HS, Huh JY, Brinkoetter MT, Chou S, Perna F, Greco D, Kilim HP, Gao C, Arampatzi K, Wang Z, Mantzoros CS. Selective capacity of metreleptin administration to reconstitute CD4+ T-cell number in females with acquired hypoleptinemia. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):E818-27. doi: 10.1073/pnas.1214554110. Epub 2013 Feb 4.
Results Reference
derived
PubMed Identifier
21660636
Citation
Aronis KN, Diakopoulos KN, Fiorenza CG, Chamberland JP, Mantzoros CS. Leptin administered in physiological or pharmacological doses does not regulate circulating angiogenesis factors in humans. Diabetologia. 2011 Sep;54(9):2358-67. doi: 10.1007/s00125-011-2201-x. Epub 2011 Jun 10.
Results Reference
derived
PubMed Identifier
21593494
Citation
Alonso-Alonso M, Ziemke F, Magkos F, Barrios FA, Brinkoetter M, Boyd I, Rifkin-Graboi A, Yannakoulia M, Rojas R, Pascual-Leone A, Mantzoros CS. Brain responses to food images during the early and late follicular phase of the menstrual cycle in healthy young women: relation to fasting and feeding. Am J Clin Nutr. 2011 Aug;94(2):377-84. doi: 10.3945/ajcn.110.010736. Epub 2011 May 18.
Results Reference
derived
Links:
URL
http://www.bidmc.org/
Description
Click here for more information about Beth Israel Deaconess Medical Center.

Learn more about this trial

Study of Leptin for the Treatment of Hypothalamic Amenorrhea

We'll reach out to this number within 24 hrs